Synbiotic SE
Frankfurt-listed investment holding focused on European cannabis, CBD and hemp sector.
Synbiotic SE is a publicly listed holding company, not a consumer brand or direct producer. It owns and invests in portfolio companies across cannabis, CBD, and hemp. Share-price claims about the company circulate heavily in cannabis stock forums, but the authoritative sources are regulatory filings and press disclosures, not stock chat boards. Holding-company structure makes it hard to assess product responsibility; always check the manufacturer named on the product label itself.
What it is
Synbiotic SE is a Munich-based holding company and investment platform structured as a Societas Europaea (SE) and listed on the Frankfurt Stock Exchange [1]. Rather than operating a single consumer brand or manufacturing facility, Synbiotic acquires and holds equity stakes in companies working across the European cannabis, CBD, and hemp value chain—including consumer brands, manufacturing, and digital platforms.
The company describes itself as a cannabis-focused investment platform with a stated focus on the European market, particularly Germany following that country's April 2024 partial legalization of adult-use cannabis [2]. Because Synbiotic is a holding company, what products or services it controls depends on its current portfolio of subsidiaries and minority investments, which changes through acquisitions and divestitures.
Ownership and regulated status
Synbiotic SE is an independent, publicly listed issuer with no single parent company. Shareholding is dispersed across many holders and changes over time. The SE (Societas Europaea) legal form is an EU-wide corporate structure that allows operations across member states under a single corporate shell.
As a Frankfurt Stock Exchange-listed company, Synbiotic is subject to German securities law (Wertpapierhandelsgesetz, WpHG) and BaFin (Bundesanstalt für Finanzdienstleistungsaufsicht) disclosure and oversight requirements. Current major shareholders, board composition, and material transactions are disclosed through mandatory regulatory filings available on the exchange and the company's investor relations website. Any enforcement action, investigation, or regulatory sanction would be published through ad-hoc disclosure (Ad-hoc-Mitteilung) as required by law.
Market focus and regulatory context
Synbiotic's stated investment focus is European cannabis, CBD, and hemp, with three broad categories: CBD and hemp consumer products, medical cannabis and adjacent pharmaceuticals, and digital or e-commerce infrastructure. Specific current holdings should be confirmed in the company's latest annual report rather than older press materials, as portfolio composition shifts.
Germany's Cannabisgesetz (CanG) of April 2024 partially legalized adult possession and home cultivation and created a legal framework for non-commercial cultivation associations [2][3]. However, the law does not create a US-style commercial recreational market; medical and scientific channels remain the main legal routes for THC products in Germany [2]. CBD products in the EU are regulated as cosmetics, food (novel food), or medicines depending on form and claims, with rules varying by country.
Notable holdings and portfolio
Synbiotic itself is not a consumer product brand; products reach end users through its portfolio companies. Historically, Synbiotic has held stakes in CBD consumer brands, hemp-derived food and cosmetic products, and online retail platforms. We do not list specific SKUs or current brands because portfolio composition changes and cannot be independently verified in real time at the time you are reading this.
If you encounter a product marketing that mentions Synbiotic or references the company, the practical question is which Synbiotic-affiliated entity is the legal manufacturer or distributor responsible for the product. That information should appear on the product label or the entity's official registration, not only in holding-company press releases. A holding-company mention does not establish product responsibility or quality; the operating entity on the label does.
Stock listing and availability
Synbiotic SE shares trade on the Frankfurt Stock Exchange and through the Xetra electronic platform under ticker SBX [1]. The stock is accessible through most European brokers; availability for non-EU investors depends on the broker's licensing and regulatory permissions. Frankfurt-listed cannabis small caps, including Synbiotic, attract significant promotional content, short-seller activity, and rumor-spreading on stock chat boards and forums Anecdote; these sources should not be treated as evidence of company performance or regulatory status No data.
Current major shareholders, board members, and material transactions are disclosed through BaFin-regulated channels and the exchange; regulatory filings are the authoritative sources for company facts. Any ongoing investigations or sanctions would appear in mandatory disclosures, not in third-party speculation.
What to verify before relying on claims
Before treating any Synbiotic-related claim as fact, check:
- Current portfolio: which subsidiaries and investments the company actually holds today should come from the latest audited annual report, available on the company's investor relations website.
- Financial claims: revenue, EBITDA, and pipeline figures must come from audited disclosures, not press releases or promotional newsletters.
- Product responsibility: for any consumer product sold under a brand name, identify the legal manufacturer or distributor entity on the label—that entity, not the holding company, is responsible for product safety, labeling compliance, and regulatory adherence.
- Regulatory status: German and EU cannabis laws are evolving; verify current status of the Cannabisgesetz pillars and CBD novel-food regulations at the time of purchase [2].
- Stock-promotion content: treat claims about share price, upcoming deals, or clinical breakthroughs with skepticism unless supported by primary regulatory filings or peer-reviewed evidence.
Last verified: November 2026. Portfolio, ownership, and regulatory status may have changed since publication; assume material details require current confirmation.
Sources
- Government Deutsche Börse (Frankfurt Stock Exchange). Xetra listing page for Synbiotic SE, ticker SBX.
- Government Bundesministerium für Gesundheit (Federal Ministry of Health, Germany). Cannabisgesetz (CanG) information portal.
- Government Bundesgesetzblatt. Gesetz zum kontrollierten Umgang mit Cannabis (Cannabisgesetz – CanG), 27 March 2024.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Aphria RX (Tilray Deutschland) — German medical cannabis cultivator and Tilray Brands subsidiary operating under BfArM cont...
- Cansativa — German medical cannabis wholesaler and exclusive distributor of state-cultivated cannabis.
- Gro-Vida — Portuguese medical cannabis cultivator with limited public documentation and B2B focus.
- Tilray Portugal — Medical cannabis producer and subsidiary of Tilray Brands operating in Portugal.
- Tyson 2.0 — Mike Tyson's cannabis brand offering flower, edibles, and lifestyle products across US leg...
- Wynk — Hemp-derived THC sparkling water brand with limited verifiable public information.